Loading...
•
Mar 31, 2022
ACADIA Q1 2022 Earnings Report
Acadia Pharmaceuticals reported an 8% increase in NUPLAZID net sales and reiterated its full-year net sales guidance.
Key Takeaways
Acadia Pharmaceuticals reported first quarter 2022 financial results, with NUPLAZID net sales increasing by 8% compared to the first quarter of 2021. The company is focused on preparing for the upcoming Advisory Committee meeting for pimavanserin in Alzheimer's disease psychosis and the NDA submission for trofinetide in Rett syndrome.
NUPLAZID net sales increased by 8% compared to Q1 2021.
FDA Advisory Committee meeting scheduled for June 17, 2022, to review sNDA for pimavanserin in Alzheimer’s disease psychosis (ADP).
FDA is targeting an August 4, 2022, action date for the resubmitted sNDA for pimavanserin for the treatment of ADP.
Trofinetide for the treatment of Rett syndrome remains on track for an NDA submission around mid-year 2022.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
Acadia is reiterating its previously provided guidance ranges
Positive Outlook
- NUPLAZID net sales guidance of $510 to $560 million.
- GAAP R&D guidance of $355 to $375 million, which includes approximately $25 million of stock-based compensation expense.
- GAAP SG&A guidance of $360 to $380 million, which includes approximately $45 million of stock-based compensation expense.